Cerity Partners’s Exelixis EXEL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$13.5M Sell
313,945
-35,271
-10% -$1.52M 0.02% 576
2025
Q4
$15.3M Buy
349,216
+167,102
+92% +$6.91M 0.02% 489
2025
Q3
$7.52M Buy
182,114
+34,795
+24% +$1.4M 0.01% 698
2025
Q2
$6.49M Sell
147,319
-20,596
-12% -$823K 0.01% 701
2025
Q1
$6.2M Buy
167,915
+94,031
+127% +$3.35M 0.01% 657
2024
Q4
$2.41M Buy
73,884
+45,890
+164% +$1.49M 0.01% 1020
2024
Q3
$726K Buy
27,994
+15,777
+129% +$392K ﹤0.01% 1570
2024
Q2
$275K Sell
12,217
-9,656
-44% -$214K ﹤0.01% 1870
2024
Q1
$519K Buy
+21,873
New +$486K ﹤0.01% 1581

Other funds holding EXEL

Cerity Partners's EXEL Position: Q1 2026 in Review

Cerity Partners reduced its Exelixis (EXEL) stake by 10% in Q1 2026, selling an estimated $1.52M and leaving 313,945 shares worth $13.5M. The position accounts for 0.02% of the portfolio, ranked #576.

Cerity Partners first reported a position in EXEL in Q1 2024 and has held it in 9 quarters since. The position peaked at $15.3M in Q4 2025. 694 funds tracked by Wall St. Rank hold EXEL as of Q1 2026.

  • Cerity Partners held 313,945 shares of Exelixis worth $13.5M as of Q1 2026.
  • Cerity Partners sold 35,271 Exelixis shares in Q1 2026, an estimated $1.52M.
  • Exelixis made up 0.02% of Cerity Partners's portfolio in Q1 2026, its #576 holding.
  • Cerity Partners first reported a position in Exelixis in Q1 2024 and has held it in 9 quarters since.
  • Cerity Partners's Exelixis position peaked at $15.3M in Q4 2025.
  • 694 funds tracked by Wall St. Rank held Exelixis as of Q1 2026.

Based on Cerity Partners's 13F filing for Q1 2026, filed 15 May 2026.